ArticleDigestive diseases and sciences2025
E2F2/MUC1 Enhances Cell Stemness of Hepatocellular Carcinoma by Regulating the Notch Signaling Pathway.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe fifth most prevalent cancer in the world, hepatocellular carcinoma (HCC), has a significant fatality rate. A cell surface mucin protein known as MUC1 is widely expressed in different cancer types. Its function in HCC has not, however, been completely investigated. The purpose of this study was to look at biological role of MUC1 in HCC.
methodsBioinformatics analysis investigated E2F2 expression in HCC tissues. Immunohistochemistry was used to detect the expression of MUC1 in HCC tissues and paracancerous tissues. qRT-PCR detected E2F2 and MUC1 expression in HCC cells. Dual-luciferase and ChIP assays verified regulatory relationship. CCK-8 assays tested cell viability. Western blot detected stem cell markers and Notch pathway-related proteins. Colony formation assays tested cell proliferation, and sphere formation assays tested the number of cell spheres formed.
resultsMUC1 was significantly upregulated in HCC tissues and cells. Knockdown of MUC1 reduced cell proliferation, expression of stem cell surface markers, the number of cell spheres formed, and Notch signaling pathway-related proteins. Bioinformatics analysis predicted that E2F2 was an upstream transcription factor of MUC1 and was substantially increased in HCC. Dual-luciferase and ChIP assays confirmed the mutual binding relationship between E2F2 and MUC1. Further reversion experiments showed that further silencing of MUC1 reversed the stimulatory effect of overexpressed E2F2 on cell stemness.
conclusionIn summary, E2F2 could upregulate the expression of MUC1 to regulate Notch signaling pathway and promote stemness of HCC cells. This study revealed a potential regulatory pathway of MUC1-mediated HCC progression, providing new ideas for HCC therapy.
Indexed as
Identifiers
40531261What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.